GLORIA PHARMA.(002437)2025-01-09 16:00Financial Performance - The estimated net profit for 2024 is projected to be 210 million CNY, representing a 74.51% increase compared to the previous year's profit of 120.33 million CNY [3]. - The net profit after deducting non-recurring gains and losses is expected to be 160 million CNY, showing a significant growth of 199.75% from 53.38 million CNY in the same period last year [3]. - Basic earnings per share are forecasted to be 0.0955 CNY, up from 0.0547 CNY in the previous year [3]. Revenue and Cost Management - Sales revenue from core products such as An Nao Wan/Pian and multi-vitamin injections has increased, contributing to overall growth [5]. - The company has successfully reduced sales, management, and financial expenses compared to the previous year, enhancing operational efficiency [5]. - The divestment of Guangzhou Yuheng Biotechnology Co., Ltd. in 2023 has eliminated its losses from impacting the company's 2024 financial results [5]. Reporting and Data Confirmation - The financial data provided is preliminary and subject to confirmation in the 2024 annual report [6].